Combining minimally invasive endoscopic sleeve gastroplasty (ESG) with the diabetes drug semaglutide can provide additional significant weight loss for patients who are not candidates for invasive weight-loss surgery, according to research that was selected for presentation at Digestive Disease Week (DDW) 2021.